Patients with mild to moderate hypertension saw their blood pressure decrease as much as 23% compared to placebo after taking Lexaria Bioscience's (LEXX) DehydraTECH-processed cannabidiol.
The company released partial results today, with additional data analyses and sleep quality to be released at a later date.
Over a 24-hour monitoring period, participants on the cannabidiol averaged a 7% decline in systolic pressure, a 3.5% decrease in diastolic pressure, and an average 5.3% decline in mean arterial pressure.
DehydraTECH-CBD was found to have its most effective results in the overnight period.
Lexaria shares are up 15% in premarket.
Recommended For You
Trending Analysis
Trending News
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.